查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1224626

光化性角化病治療美國市場規模、份額和趨勢分析:按治療方法、藥物類別、產品、用途、市場預測,2023-2030年

U.S. Actinic Keratosis Treatment Market Size, Share & Trends Analysis Report By Therapy (Topical/Drugs, Surgery, Photodynamic Therapy), By Drug Class, By Product, By End-use, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

美國光化性角化病治療市場的增長和趨勢

根據 Grand View Research, Inc. 的最新報告，美國光化性角化病治療市場規模預計到 2030 年將達到 29.4 億美元，預測期內以 3.03% 的複合年增長率擴大。 光化性角化病治療服務的廣泛應用和對光化性角化病 (AK) 治療的認識不斷提高預計將推動市場增長。 此外，對 AK 微創治療的強勁需求和局部治療方案的不斷採用也有望支持市場增長。 例如，根據美國國立衛生研究院的數據，5%的5-氟尿嘧啶乳膏是光化性角化病的首選和最佳一線治療藥物。

消費者對 AK 等皮膚病的認識不斷提高是該市場的主要增長動力。 增加對這種疾病的診斷和治療策略的了解正在推動 AK 治療的整體採用。 5-氟尿嘧啶、雙氯芬酸和咪奎莫特等定點驅動的治療藥物有望在未來幾年見證更大的市場滲透。 例如，臨床試驗表明，用含有咪奎莫特的製劑治療的患者達到了大約 75% 的清除率。

此外，與局部光化性角化病製劑相關的高安全性和耐受性因素增加了對治療光化性角化病的局部藥物的需求。 例如，在 clinicaltrials.gov 上發布的局部 AK 的 3 期臨床試驗發現局部 AK 沒有嚴重的副作用。 雖然一些製劑會引起局部皮膚刺激，如過敏，但更新的局部製劑，如替凡尼鹼和 ingenol mebutate 顯示出更好的耐受性，有望推動市場增長。

根據 NIH 的說法，與單一療法相比，光動力療法和局部藥物的結合提高了清除率。 此外，根據發表在 Healio 雜誌上的一項研究，20% 氨基乙□丙酸和 PDT 的組合在 AK 中顯示出良好的結果，幾乎沒有副作用。 因此，預計在預測期內，治療光化性角化病的聯合療法將推動市場增長。

此外，主要進入者正在採取戰略舉措，例如產品發布、擴張和合作夥伴關係等戰略，以增加他們的市場份額。 例如，2021 年 2 月，領先的生物製藥公司 Athenex, Inc. 在美國推出了 Klisyri 用於治療頭皮光化性角化病。我們宣布將獲得更多領域的許可。

美國光化性角化病治療市場報告要點

由於完全治癒的高需求和冷凍療法的滲透，外科領域的份額最大。

光動力療法由於其高位點特異性和極少的副作用記錄了最快的增長速度

由於 Fluoplex、Carac 和 Fdex 的強勁商業表現以及對治療早期疾病的外用製劑的高需求，核甘代謝抑製劑部分在 2022 年佔據了最大的市場

/p>

從產品來看，5-氟尿嘧啶細分市場預計將在 2022 年主導美國光化性角化病治療市場，而替凡尼細分市場有望快速增長

到 2022 年，由於在醫院進行的醫生主導的手術增加，醫院部分將成為最大的部分

主導市場的主要參與者是 Bausch Health Companies, Inc.、LEO Pharma A/S、Almirall, S.A. 和 Biofrontera AG。

內容

第 1 章調查方法及範圍

  • 市場細分和範圍
    • 細分範圍
    • 區域範圍
  • 調查方法
  • 資訊採購
    • 購買的數據庫：
    • GVR 內部數據庫
    • 次要資訊
    • 初步調查
    • 初步調查的內容
  • 資訊或數據分析
    • 數據分析模型
  • 市場制定和驗證
  • 模型詳細資訊
    • 商品流分析
      • 方法：產品流方法
  • 調查假設
  • 二級資訊列表
  • 縮寫列表
  • 目的

第 2 章執行摘要

  • 市場展望
  • 競爭考慮

第 3 章美國光化性角化病治療市場變量、趨勢和範圍

  • 市場系列展望
    • 母公司市場
  • 市場動態
    • 市場促進因素分析
      • 疾病流行率增加
      • 預防策略
      • 易於獲得治療
    • 市場抑制因素分析
      • 缺乏消費者意識
      • 一般滲透
  • 描繪滲透率和增長前景
  • 流感疫苗：市場分析工具
    • 行業分析 - 波特五力分析
    • PESTLE 分析
  • 監管框架
  • 價格分析

第 4 章美國光化性角化病治療市場細分分析，按治療方式，2018-2030 年（百萬美元）

  • 定義和範圍
  • 2022 年和 2030 年治療市場份額分析
  • 部門儀表板
  • 美國光化性角化病治療市場，按治療方式，2018-2030 年
  • 2018-2030 年市場規模和預測、趨勢分析
    • 外用/藥物
    • 手術
      • 冷凍療法
      • 其他
    • 光動力療法

第 5 章美國光化性角化病治療市場細分分析，按產品分類，2018-2030 年（百萬美元）（數量、銷售額）

  • 定義和範圍
  • 2022 年和 2030 年產品市場份額分析
  • 部門儀表板
  • 美國光化性角化病治療市場，副產品，2018-2030
  • 2018-2030 年市場規模和預測、趨勢分析
    • 5-氟尿嘧啶
      • Carac
      • Fluoroplex
      • Actikerall
      • Tolak
      • 其他
    • Diclofenac
      • Solaraze
      • Voltaren
      • Pennsaid
      • 其他
    • Imiquimod
      • Aldara
      • Zyclara
      • 其他
    • Tirbanibulin
    • Capecitabine
      • Xeloda
      • 其他
    • Aminolevulinic acid
      • Ameluz
      • Levulan
    • Porfimer sodium
    • 其他
      • Gemzar
      • Clolar
      • Vidaza
      • Metvix
      • 其他

第 6 章美國光化性角化病治療市場細分分析，按藥物類別，2018-2030 年（百萬美元）

  • 定義和範圍
  • 2022 年和 2030 年藥物類別市場份額分析
  • 部門儀表板
  • 2018-2030 年按藥物類別劃分的美國光化性角化病治療市場
  • 2018-2030 年市場規模和預測、趨勢分析
    • 核甘代謝抑制劑
    • 非甾體抗炎藥
    • 免疫反應調節劑
    • 增光劑
    • 其他

第 7 章美國光化性角化病治療市場細分分析，按最終用途，2018-2030（百萬美元）

  • 定義和範圍
  • 2022 年和 2030 年終端用途市場份額分析
  • 部門儀表板
  • 按最終用途劃分的美國光化性角化病治療市場 2018-2030
  • 2018-2030 年市場規模和預測、趨勢分析
    • 醫院
    • 私人診所
    • 家庭護理
    • 其他

第 8 章美國光化性角化病治療市場細分分析，按地區劃分，2018-2030 年（百萬美元）

  • 定義和範圍
  • 2022 年和 2030 年區域市場份額分析
  • 區域市場儀表板
  • 區域市場概況
  • SWOT 分析
  • 2022-2030 年市場規模、預測、收入和趨勢分析
    • 美國
      • 美國
      • 主要國家動態
      • 競爭場景
      • 監管框架
      • 贖回場景

第 9 章美國光化性角化病治療市場-競爭分析

  • 主要市場進入者的近期趨勢和影響分析
    • Ansov 矩陣
    • 熱圖分析
    • 對主要交易和戰略聯盟的分析
      • 合資企業
      • 許可協議
      • 產品發布
      • 會議和活動
  • 公司分類
    • 創新者
    • 市場領導者
  • 供應商情況
    • 主要分銷商和渠道合作夥伴列表
    • 主要客戶
  • 上市公司
    • 競爭儀錶盤分析
      • 市場差異化因素
  • 私人公司
    • 主要初創公司名單
  • 公司簡介
    • Bausch Health Companies, Inc.
      • 公司概況
      • 財務業績
      • 產品基準
      • 戰略舉措
    • LEO Pharma A/S
      • 公司概況
      • 財務業績
      • 產品基準
      • 戰略舉措
    • Almirall, SA
      • 公司概況
      • 財務業績
      • 產品基準
      • 戰略舉措
    • Biofrontera AG
      • 公司概況
      • 財務業績
      • 產品基準
      • 戰略舉措
    • GALDERMA
      • 公司概況
      • 財務業績
      • 產品基準
      • 戰略舉措
    • Sun Pharmaceutical Industries Ltd
    • 公司概況
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Novartis AG
    • 公司概況
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Hill Dermaceuticals, Inc.
    • 公司概況
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Viatris Inc.
    • 公司概況
    • 財務業績
    • 產品基準
    • 戰略舉措
  • 3M
    • 公司概況
    • 財務業績
    • 產品基準
    • 戰略舉措
Product Code: GVR-4-68040-027-1

U.S. Actinic Keratosis Treatment Market Growth & Trends:

The U.S. actinic keratosis treatment market size is expected to reach USD 2.94 billion by 2030, expanding at a CAGR of 3.03% over the forecast period, according to a new report by Grand View Research, Inc. The wide availability of actinic keratosis therapeutic services and the surge in awareness for actinic keratosis (AK) treatment are anticipated to drive market growth. Moreover, the strong demand for minimally invasive therapies for AK and escalated adoption of topical regimens are expected to support market growth. For instance, according to the National Institute for Health and Care Research, 5% fluorouracil cream is the most preferred and best first-line treatment for actinic keratosis.

The growing consumer awareness about dermatological diseases, such as AK, is a major growth booster for the market. An increase in knowledge about diagnostics and treatment strategies for the disease has driven the overall adoption of AK treatment. Field-directed treatments, such as 5-fluorouracil, diclofenac, and imiquimod are expected to witness greater market penetration over the coming years. For instance, clinical trials demonstrated that the patients treated with imiquimod-containing formulation achieved a clearance of around 75%.

Moreover, higher safety and tolerability factors associated with topical actinic keratosis preparations have increased the demand for topical drugs to treat actinic keratosis. For instance, according to phase-3 clinical trials of topical agents for AK published at clinicaltrials.gov, no severe adverse effects were noted from topical AK therapies. Some formulations produced some local skin irritations like allergies but novel topical preparations such as tirbanibulin, and ingenol mebutate showed more favorable tolerability profiles, which is expected to increase the market growth.

According to the NIH, the combination of photodynamic therapy with topical formulations improves the clearance rates as compared to monotherapy alone. Moreover, according to the study published in Healio, the combination therapy of aminolevulinic acid 20% and PDT has shown positive outcomes with fewer side effects in AK. Thus, a strong promise from combination therapies in the treatment of actinic keratosis is anticipated to propel the market growth during the forecast period.

Moreover, leading participants are undertaking strategic initiatives such as product launches, expansion, and partnerships among other strategies to increase their market share. For instance, in February 2021 Athenex, Inc. a leading biopharmaceutical company launched Klisyri for the treatment of actinic keratosis of the scalp in the U.S. Along with this launch, the company announced the licensing of additional territories for tirbanibulin to its partner PharmaEssentia Corp.

U.S. Actinic Keratosis Treatment Market Report Highlights:

  • The surgery segment held the largest share owing to the higher demand for complete disease eradication and high penetration of cryotherapy procedures
  • The photodynamic therapy segment registered the fastest growth rate because of high site specificity and less incidence of side effects
  • The nucleoside metabolic inhibitors segment accounted for the largest market in 2022 due to the strong commercial performance of Fluroplex, Carac, and Efudex along with a higher demand for topical formulations to treat the initial stages of the disease
  • Based on product, the 5-fluorouracil segment dominated the U.S. actinic keratosis treatment market in 2022, whereas, the tirbanibulin segment is anticipated to be the fastest-growing segment
  • The hospitals segment was the largest in 2022 owing to increasing physician-assisted procedures performed in hospitals
  • Key players dominating the market include Bausch Health Companies, Inc.; LEO Pharma A/S; Almirall, S.A.; and Biofrontera AG

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment scope
    • 1.1.2 Regional scope
    • 1.1.3 Estimates and forecast timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database:
    • 1.3.2 GVR's internal database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary research
    • 1.3.5 Details of primary research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data analysis models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach: Commodity Flow Approach
  • 1.7 Research Assumptions
  • 1.8 List of Secondary Sources
  • 1.9 List of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective 1
    • 1.10.2 Objective 2
    • 1.10.3 Objective 3
    • 1.10.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Competitive Insights

Chapter 3 U.S. Actinic Keratosis Treatment Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market
  • 3.2 Market Dynamics
    • 3.2.1 Market drivers analysis
      • 3.2.1.1 Increasing disease prevalence
      • 3.2.1.2 Preventive strategies
      • 3.2.1.3 Easy availability of treatment
    • 3.2.2 Market restraint analysis
      • 3.2.2.1 Lack of consumer awareness
      • 3.2.2.2 Generic penetration
  • 3.3 Penetration & Growth Prospect Mapping
  • 3.4 Influenza Vaccine: Market Analysis Tools
    • 3.4.1 Industry analysis - Porter's
    • 3.4.2 PESTLE analysis
  • 3.5 Regulatory Framework
  • 3.6 Pricing Analysis

Chapter 4 U.S. Actinic Keratosis Treatment Market Segment Analysis, By Therapy, 2018 - 2030 (USD Million)

  • 4.1 Definition and Scope
  • 4.2 Therapy Market Share Analysis, 2022 & 2030
  • 4.3 Segment Dashboard
  • 4.4 U.S. Actinic Keratosis Treatment Market, by Therapy, 2018 to 2030
  • 4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 4.5.1 Topical/Drugs
      • 4.5.1.1 Topical/Drugs market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.2 Surgery
      • 4.5.2.1 Surgery market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.5.2.2 Cryotherapy
      • 4.5.2.2.1 Cryotherapy market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.5.2.3 Others
      • 4.5.2.3.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.3 Photodynamic Therapy
      • 4.5.3.1 Photodynamic therapy market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 5 U.S. Actinic Keratosis Treatment Market Segment Analysis, By Product 2018 - 2030 (USD Million) (Volume, Number of Units Sold)

  • 5.1 Definition and Scope
  • 5.2 Product Market Share Analysis, 2022 & 2030
  • 5.3 Segment Dashboard
  • 5.4 U.S. Actinic Keratosis Treatment Market, by Product, 2018 to 2030
  • 5.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 5.5.1 5-fluorouracil
      • 5.5.1.1 5-fluorouracil market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.1.2 Carac
      • 5.5.1.2.1 Carac market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.1.3 Fluoroplex
      • 5.5.1.3.1 Fluoroplex market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.1.4 Actikerall
      • 5.5.1.4.1 Actikerall market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.1.5 Tolak
      • 5.5.1.5.1 Tolak market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.1.6 Others
      • 5.5.1.6.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
    • 5.5.2 Diclofenac
      • 5.5.2.1 Diclofenac market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.2.2 Solaraze
      • 5.5.2.2.1 Solaraze market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.2.3 Voltaren
      • 5.5.2.3.1 Voltaren market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.2.4 Pennsaid
      • 5.5.2.4.1 Pennsaid market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.2.5 Others
      • 5.5.2.5.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
    • 5.5.3 Imiquimod
      • 5.5.3.1 Imiquimod market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.3.2 Aldara
      • 5.5.3.2.1 Aldara market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.3.3 Zyclara
      • 5.5.3.3.1 Zyclara market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.3.4 Others
      • 5.5.3.4.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
    • 5.5.4 Tirbanibulin
      • 5.5.4.1 Tirbanibulin market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
    • 5.5.5 Capecitabine
      • 5.5.5.1 Capecitabine market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.5.2 Xeloda
      • 5.5.5.2.1 Xeloda market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.5.3 Others
      • 5.5.5.3.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
    • 5.5.6 Aminolevulinic acid
      • 5.5.6.1 Aminolevulinic acid market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.6.2 Ameluz
      • 5.5.6.2.1 Ameluz market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.6.3 Levulan
      • 5.5.6.3.1 Levulan market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
    • 5.5.7 Porfimer sodium
      • 5.5.7.1 Porfimer sodium market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
    • 5.5.8 Others
      • 5.5.8.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.8.2 Gemzar
      • 5.5.8.2.1 Gemzar market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.8.3 Clolar
      • 5.5.8.3.1 Clolar market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.8.4 Vidaza
      • 5.5.8.4.1 Vidaza market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.8.5 Metvix
      • 5.5.8.5.1 Metvix market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
      • 5.5.8.6 Others
      • 5.5.8.6.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)

Chapter 6 U.S. Actinic Keratosis Treatment Market Segment Analysis, By Drug Class, 2018 - 2030 (USD Million)

  • 6.1 Definition and Scope
  • 6.2 Drug Class Market Share Analysis, 2022 & 2030
  • 6.3 Segment Dashboard
  • 6.4 U.S. Actinic Keratosis Treatment Market, by Drug Class, 2018 to 2030
  • 6.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 6.5.1 Nucleoside metabolic inhibitors
      • 6.5.1.1 Nucleoside metabolic inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.2 Nonsteroidal anti-inflammatory drugs
      • 6.5.2.1 Nonsteroidal anti-inflammatory drugs market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.3 Immune response modifiers
      • 6.5.3.1 Immune response modifiers market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.4 Photoenhancers
      • 6.5.4.1 Photoenhancers market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.5 Others
      • 6.5.5.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7 U.S. Actinic Keratosis Treatment Market Segment Analysis, By End-use, 2018 - 2030 (USD Million)

  • 7.1 Definition and Scope
  • 7.2 End-use Market Share Analysis, 2022 & 2030
  • 7.3 Segment Dashboard
  • 7.4 U.S. Actinic Keratosis Treatment Market, by End-use, 2018 to 2030
  • 7.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 7.5.1 Hospitals
      • 7.5.1.1 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.2 Private clinics
      • 7.5.2.1 Private clinics market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.3 Homecare
      • 7.5.3.1 Homecare market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.4 Others
      • 7.5.5.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 U.S. Actinic Keratosis Treatment Market Segment Analysis, By Region, 2018 - 2030 (USD Million)

  • 8.1 Definition & Scope
  • 8.2 Regional Market Share Analysis, 2022 & 2030
  • 8.3 Regional Market Dashboard
  • 8.4 Regional Market Snapshot
  • 8.5 SWOT Analysis
  • 8.6 Market Size, & Forecasts, Revenue and Trend Analysis, 2022 to 2030
    • 8.6.1 U.S.
      • 8.6.1.1 U.S. actinic keratosis treatment market estimates and forecasts, 2018 - 2030 (USD Million)
      • 8.6.1.2 U.S.
      • 8.6.1.2.1 Key Country Dynamics
      • 8.6.1.2.2 Competitive Scenario
      • 8.6.1.2.3 Regulatory Framework
      • 8.6.1.2.4 Reimbursement Scenario

Chapter 9 U.S. Actinic Keratosis Treatment Market - Competitive Analysis

  • 9.1 Recent Developments & Impact Analysis, by Key Market Participants
    • 9.1.1 Ansoff matrix
    • 9.1.2 Heat map analysis
    • 9.1.3 Major Deals and Strategic Alliances Analysis
      • 9.1.3.1 Joint Ventures
      • 9.1.3.2 Licensing Agreements
      • 9.1.3.3 Product Launches
      • 9.1.3.1 Conferences and Campaigns
  • 9.2 Company Categorization
    • 9.2.1 Innovators
    • 9.2.2 Market Leaders
  • 9.3 Vendor Landscape
    • 9.3.1 List of key distributors and channel partners
    • 9.3.2 Key customers
  • 9.4 Public Companies
    • 9.4.1 Competitive Dashboard Analysis
      • 9.4.1.1 Market Differentiators
  • 9.5 Private Companies
    • 9.5.1 List of key emerging companies
  • 9.6 Company Profiles
    • 9.6.1 Bausch Health Companies, Inc
      • 9.6.1.1 Company overview
      • 9.6.1.2 Financial performance
      • 9.6.1.3 Product benchmarking
      • 9.6.1.4 Strategic Initiatives
    • 9.6.2 LEO Pharma A/S
      • 9.6.2.1 Company overview
      • 9.6.2.2 Financial performance
      • 9.6.2.3 Product benchmarking
      • 9.6.2.4 Strategic Initiatives
    • 9.6.3 Almirall, S.A
      • 9.6.3.1 Company overview
      • 9.6.3.2 Financial performance
      • 9.6.3.3 Product benchmarking
      • 9.6.3.4 Strategic Initiatives
    • 9.6.4 Biofrontera AG
      • 9.6.4.1 Company overview
      • 9.6.4.2 Financial performance
      • 9.6.4.3 Product benchmarking
      • 9.6.4.4 Strategic Initiatives
    • 9.6.5 GALDERMA
      • 9.6.5.1 Company overview
      • 9.6.5.2 Financial performance
      • 9.6.5.3 Product benchmarking
      • 9.6.5.4 Strategic Initiatives
    • 9.6.6 Sun Pharmaceutical Industries Ltd
      • 9.6.6.1 Company overview
      • 9.6.6.2 Financial performance
      • 9.6.6.3 Product benchmarking
      • 9.6.6.4 Strategic Initiatives
    • 9.6.7 Novartis AG
      • 9.6.7.1 Company overview
      • 9.6.7.2 Financial performance
      • 9.6.7.3 Product benchmarking
      • 9.6.7.4 Strategic initiatives
    • 9.6.8 Hill Dermaceuticals, Inc
      • 9.6.8.1 Company overview
      • 9.6.8.2 Financial performance
      • 9.6.8.3 Product benchmarking
      • 9.6.8.4 Strategic initiatives
    • 9.6.9 Viatris Inc.
      • 9.6.9.1 Company overview
      • 9.6.9.2 Financial performance
      • 9.6.9.3 Product benchmarking
      • 9.6.9.4 Strategic initiatives
    • 9.6.10 3M
      • 9.6.10.1 Company overview
      • 9.6.10.2 Financial performance
      • 9.6.10.3 Product benchmarking
      • 9.6.10.4 Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Leading market players anticipated to witness the highest growth
  • Table 4 U.S. actinic keratosis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 6 U.S. actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 7 U.S. actinic keratosis treatment market, by product, 2018 - 2030 (USD Million) (number of units sold)
  • Table 8 U.S. actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 Product pipeline
  • Table 10 Regulatory framework
  • Table 11 Comparative study of brands available for diclofenac
  • Table 12 Comparative study of brands available for 5-Fluorouracil
  • Table 13 Comparative study of brands available for Imiquimod
  • Table 14 Treatments currently available for management of AK
  • Table 15 Comparative study of brands available for 5-Fluorouracil
  • Table 16 Comparative study of brands available for diclofenac
  • Table 17 Comparative study of brands available for Imiquimod
  • Table 18 Comparative study of brands available for Tirbanibulin
  • Table 19 Comparative study of brands available for Capecitabine
  • Table 20 Comparative study of brands available for Aminolevulinic acid
  • Table 21 Comparative study of brand available for Porfimer sodium
  • Table 22 Comparative study of brands available under others segment
  • Table 23 Key topical products for actinic keratosis, 2022
  • Table 24 Key surgical procedures for actinic keratosis, 2022
  • Table 25 Key photodynamic therapeutics for actinic keratosis, 2022
  • Table 26 Key nucleoside metabolic inhibitors for actinic keratosis
  • Table 27 Key NSAIDs for actinic keratosis
  • Table 28 Key immune response modifiers for actinic keratosis
  • Table 29 Key photo enhancers for actinic keratosis
  • Table 30 Other drug classes for actinic keratosis
  • Table 31 Key physician-managed treatment for actinic keratosis
  • Table 32 Key home-based treatment for actinic keratosis
  • Table 33 Leading market players anticipated to witness the highest growth
  • Table 34 Key companies undergoing expansions
  • Table 35 Key companies undertaking acquisitions
  • Table 36 Key companies undergoing collaborations
  • Table 37 Key companies launching new products/services
  • Table 38 Key companies undergoing other strategies

List of Figures

  • Fig. 1 U.S. actinic keratosis treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Segment snapshot
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Penetration & growth prospect mapping
  • Fig. 14 Consumer behavior analysis
  • Fig. 15 Market driver relevance analysis (Current & future impact)
  • Fig. 16 Market restraint relevance analysis (Current & future impact)
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTLE analysis
  • Fig. 19 U.S. actinic keratosis treatment market: Product outlook and key takeaways
  • Fig. 20 U.S. actinic keratosis treatment market: Product movement analysis
  • Fig. 21 Product segment dashboard
  • Fig. 22 5-Fluorouracil market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
  • Fig. 23 Diclofenac market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
  • Fig. 24 Imiquimod market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
  • Fig. 25 Tirbanibulin market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
  • Fig. 26 Capecitabine market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
  • Fig. 27 Aminolevulinic acid market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
  • Fig. 28 Porfimer sodium market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
  • Fig. 29 Others market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
  • Fig. 30 U.S. actinic keratosis treatment market: Therapy outlook and key takeaways
  • Fig. 31 U.S. actinic keratosis treatment market: Therapy movement analysis
  • Fig. 32 Therapy segment dashboard
  • Fig. 33 Topical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Surgery market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Photodynamic therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. actinic keratosis treatment market: Drug class outlook and key takeaways
  • Fig. 37 U.S. actinic keratosis treatment market: Drug class movement analysis
  • Fig. 38 Drug class segment dashboard
  • Fig. 39 Nucleoside metabolic inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Nonsteroidal anti-inflammatory drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Immune response modifiers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Photo enhancers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. actinic keratosis treatment market: End-use outlook and key takeaways
  • Fig. 45 U.S. actinic keratosis treatment market: End-use movement analysis
  • Fig. 46 End-use segment dashboard
  • Fig. 47 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Private clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Homecare market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 U.S. actinic keratosis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Ansoff Matrix
  • Fig. 54 Heat map analysis
  • Fig. 55 Market differentiators
  • Fig. 56 Market participant categorization
  • Fig. 57 U.S. actinic keratosis treatment market share analysis, 2022
  • Fig. 58 Strategic framework